Clinical TrialJul 13, 2026, 04:01 PM
Erasca ERAS-0015 Shows 57% uORR in Pancreatic Cancer; Plans Phase 3
AI Summary
Erasca, Inc. announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing encouraging monotherapy responses with a 57% unconfirmed Overall Response Rate (uORR) in 2L+ KRAS G12X pancreatic cancer. The drug was generally well-tolerated, and promising combination potential with panitumumab was observed. Based on these results, Erasca plans to accelerate development, initiating a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 trial in pancreatic cancer in 2027, and another Phase 3 trial in lung cancer in H2 2027 to H1 2028.
Key Highlights
- ERAS-0015 showed 57% uORR in 2L+ KRAS G12X pancreatic cancer at 32 mg QD.
- Monotherapy was generally well-tolerated with 100% median relative dose intensity.
- Combination with panitumumab showed no DLTs and encouraging safety data.
- Additional ERAS-0015 monotherapy and combination data expected H1 2027.
- Company plans to initiate a potentially registration-enabling trial in lung cancer in H1 2027.
- A Phase 3 pivotal trial in pancreatic cancer is planned for 2027.
- An additional Phase 3 pivotal trial in lung cancer is planned for H2 2027 to H1 2028.
Price Impact
More from ERAS